Saturday, 15th February 32nd Lorne Cancer 2020

Resolving Biology to Advance Human Health

Nicholas Navin, MD Anderson Cancer Center
Singe cell analysis of human tissues

Ghamdan Al-Eryani, Garvan Institute
Applications of CITE-Seq to cancer immunology

Fernando Rossello, University of Melbourne Centre for Cancer Research
Same sample single nuclei RNA and ATACseq data integration.

Rachel Thijssen, WEHI
Uncovering the complexities of emergent resistance to targeted therapies with single cell technologies

Closing Remarks
Howard Roberts, Millennium Science
Aigu Lin, 10X Genomics

• What is next in cancer immunotherapy - Antoni Ribas
• MAIT Cells Promote Tumor Initiation, Growth, and Metastases via Tumor MR1 - Michele Teng
• Novel ovarian cancer treatment using CAR-T cells targeting the non-functional P2X7 receptor - Carmela Ricciardelli
• Use of phenotypic and spatial data acquired from multiplex immunohistochemistry to model endogenous immune reactivity in the colon cancer tumor microenvironment. - Timothy Frankel
• Mechanistic insights into radiation-induced in situ immunization: from mice to patients and back - Sandra Demaria

• Combinatorial knock-out of Rap1GDS1 and RhoA leads to lethality in KRAS-driven Non-Small Cell Lung Cancer - E. Alejandro Sweet-Cordero
• Using single-nuclei RNA-sequencing for dissection of rare neuroendocrine tumours - Richard Tothill
• Pancreatic adenocarcinoma single cell atlas. Decoding pancreatic cancer using single cell sequencing. - Fernando J. Rossello
• A quantitative pathway-based whole genome rare variant analysis of 1,600 individuals affected by sarcoma - David Thomas

Combinations of Targeted Therapy and immunotherapy; Preclinical and Clinical Perspectives

Chair: Prof Grant McArthur Speaker: Prof Toni Ribas

The Peter Mac Experience with Comprehensive Genomic Profiling - The New Standard of Care in Tissue Pathology

Comprehensive genomic profiling (CGP) describes technologies that allow profiling of all major types of genomic alterations, including simple nucleotide variation (SNV and indel), somatic copy number alteration (SCNA), structural variation (SV), and aggregate markers of genome damage such as Tumour Mutation Burden (TMB) and microsatellite instability (MSI). CGP could lead to improved access to molecularly targeted therapies for cancer patients but, aside from a few accredited commercial and academic providers, is not widely used in routine pathology practice. Aspects of CGP presenting barriers to broad adoption include cost, technical complexity, lack of reimbursement, and a perceived lack of clinical utility. Here we summarise the experience of Peter Mac’s Pathology Department in providing CGP in the translation research setting over three years of testing for personalised medicine trials. We find that characterising tumours using a comprehensive in-house clinical research panel provides useful diagnostic and predictive information that impacts patient care in a number of cases however at relatively high per sample cost. In comparison, we describe our experience with one of the first kit-based CGP research products on the Australian market meeting the requirements for routine CGP.

Dr. Andrew Fellowes, Clinical Informatics | Molecular Research & Development

• Peter Mac Experience with Comprehensive Genomic Profiling – The New Standard of Care in Tissue Pathology? - Andrew Fellowes

• Escapades into the world of mutagenesis - Serena Nik-Zainal
• Spatially resolved intra tumour heterogeneity in primary and metastatic breast cancer defined by high-throughput CUTseq - Xiaolu Zhang
• The genomic landscape of the in situ to invasive ductal carcinoma transition shaped by the immune system - Anne Trinh

• STEM CELLS PLAY A ROLE IN HUMAN LEUKEMIA FROM THE BEGINNING TO THE END - John Dick

Includes After Dinner Speaker:

Age Journalist Richard Baker